Stephen Charles

Stephen is the CEO for SATOR Therapeutics, an early stage company with an oncolytic virus platform; and the CTO for Atalantos Biotechnology, an early stage company with a non-addictive therapeutic designed specifically for drug and/or alcohol detox that results in rapid physical restoration and mental clarity and provides an optimal framework for the therapeutic work necessary for sustained recovery. Prior to BioEnterprise, he founded Oligasis (now known as Kodiak), a biopharmaceutical company developing treatments for retinal diseases, and played key development roles in multiple successful, marketed product platforms, including J&J Ortho’s Vitros central laboratory diagnostic system, GE Healthcare’s Biacore biosensor, CooperVision’s Proclear range of contact lenses, Medtronic’s Endeavor drug-eluting coronary stent, and several PEGylated biopharmaceutical products. Stephen is an inventor on over 25 patents, and earned his B.Sc. and Ph.D. degrees in biochemistry from the University of London.